Stuart Spencer

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · The Lancet Oncology · 2014 · 1.4K citations

Olaparib Maintenance Therapy, Serous Ovarian Cancer, Medicine +8

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · The Lancet Oncology · 2016 · 444 citations · Full text

Overall Survival, Medicine, Metronomic Therapy +10

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

Darren Hodgson, Brian Dougherty, Zhongwu Lai et al. · British Journal of Cancer · 2018 · 225 citations · Full text

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

Michael Friedländer, Ursula A. Matulonis, Charlie Gourley et al. · British Journal of Cancer · 2018 · 177 citations · Full text

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

Caroline Robert, Reinhard Dummer, Ralf Gutzmer et al. · The Lancet Oncology · 2013 · 169 citations

Medicine, Melanoma, Pharmacology +6